pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2016-26-4-399-419pulmo-741Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESДиагностика и лечение идиопатического легочного фиброза Федеральные клинические рекомендацииDiagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal GuidelinesЧучалинА. Г.ChuchalinA. G.

д. м. н., профессор, академик РАН, директор ФГБУ «НИИ пульмонологии» ФМБА России, главный внештатный специалист терапевт-пульмонолог Минздрава России; тел. / факс: (495) 465-52-64;

MD, Professor, Academician of Russian Science Academy, Director of Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; Chief Therapeutist and Pulmonologist of Healthcare Ministry of Russia; tel. / fax: 495) 465-52-64;

chuchalin@inbox.ruАвдеевС. Н.AvdeevS. N.

д. м. н., профессор, зам. директора по научной работе, зав. клиническим отделом ФГБУ «НИИ пульмонологии» ФМБА России; тел. / факс: (495) 465-52-64;

MD, Professor, Deputy Director for Science, Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel. / fax: (495) 465-52-64;

serg_avdeev@list.ruАйсановЗ. Р.AisanovZ. R.

д. м. н., профессор, зав. отделом клинической физиологии и клинических исследований ФГБУ «НИИ пульмонологии» ФМБА России; тел.: (495) 965-34-66;

MD, Professor, Head of Division of Clinical Physiology and Clinical Trials, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (495) 965-34-66;

aisanov@mail.ruБелевскийА. С.BelevskiyA. S.

д. м. н., профессор, зав. кафедрой пульмонологии ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России; тел.: (495) 965-09-27;

MD, Professor, Head of Department of Pulmonology, Faculty of Postgraduate Physician Training, N.I.Pirogov Russian National State Research Medical University", Healthcare Ministry of Russia; tel.: (495) 965-09-27;

pulmobas@yandex.ruДемураС. А.DemuraS. A.

к. м. н., доцент кафедры патологической анатомии им. А.И.Струкова ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России; тел.: (499) 708 37 65,

PhD, Associate Professor at the A.I.Strukov Department of Pathological Anatomy, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (499) 708 37 65

sarah3618@gmail.comИльковичМ. М.Il'kovichM. M.

д. м. н., профессор, директор НИИ интерстициальных и орфанных заболеваний легких, зав. кафедрой пульмонологии ФПО ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России; тел.: (812) 338-66-10;

MD, Professor, Director of Academic and Clinical Center of Interstitial and Orphan Diseases, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 338-66-10;

mih.ilkovich@yandex.ruКоганЕ. А.KoganE. A.

д. м. н., профессор, зав. кафедрой патологической анатомии им. А.И.Струкова ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России; тел.: (499) 708-37-65, (495) 438-23-11;

MD, Professor, Head of A.I.Strukov Department of Pathological Anatomy, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia; tel.: (499) 708-37-65, (495) 438-23-11;

koganevg@gmail.comСамсоноваМ. В.SamsonovaM. V.

д. м. н., зав. лабораторией патологической анатомии и иммунологии ФГБУ «НИИ пульмонологии» ФМБА России; тел.: (495) 465-53-84;

MD, Head of Laboratory of Pathology and Immunology, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (495) 465-53-84;

samary@mail.ruСперанскаяА. А.SperanskayaA. A.

д. м. н., профессор, доцент кафедры рентгенологии и радиационной медицины ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России; тел.: (812) 338-60-66;

MD, Professor, Associate Professor at Department of Medical Radiology, Academician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia; tel.: (812) 346-12-84;

a.spera@mail.ruТюринИ. Е.TyurinI. E.

д. м. н., профессор, зав. кафедрой рентгенологии и радиологии ГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России, главный внештатный специалист по лучевой диагностике Минздрава России; тел.: (903) 758-46-52;

MD, Professor, Head of Department of Radiology, Russian State Medical Academy of Postgraduate Physician Training, Healthcare Ministry of Russia; Chief Radiologist of Healthcare Ministry of Russia; tel.: (903) 758-46-52;

igortyurin@gmail.comЧерняевА. Л.ChernyaevA. L.

д. м. н., профессор, зав. отделом патологии ФГБУ «НИИ пульмонологии» ФМБА России; тел.: (495) 465-53-84;

MD, Professor, Head of Division of Pathology, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (495) 465-53-84;

cheral12@hotmail.comЧернякБ. А.ChernyakB. A.

д. м. н., профессор, зав. кафедрой клинической аллергологии и иммунологии ГБОУ ДПО «Иркутская государственная медицинская академия последипломного образования» Минздрава России; тел.: (902) 568-78-70;

MD, Professor, Head of Department of Clinical Allergology and Immunology,  Irkutsk State Medical Academy of Postgraduate Training, Healthcare Ministry of Russia; tel.: (902) 568-78-70;

ba.chernyak@gmail.comЧернякА. В.ChernyakA. V.

к. м. н., зав. лабораторией функциональных и ультразвуковых методов исследования ФГБУ «НИИ пульмонологии» ФМБА России; тел.: (495) 465-53-84;

PhD, Head of Laboratory of Functional and Ultra-sound Investigations; Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (495) 465-53-84;

achi2000@mail.ruШмелевЕ. И.ShmelevE. I.

д. м. н., профессор, зав. отделом дифференциальной диагностики туберкулеза ФГБНУ «Центральный НИИ туберкулеза» РАМН, залуженный деятель науки России; тел.: (499) 785-90-31;

MD, Professor, Head of Division of Differential Diagnostics of Tuberculosis, Federal Central Research Institute of Tuberculosis, Russian Medical Science Academy; tel.: (499) 785-90-31;

shmelev@mgts.ruФГБУ «НИИ пульмонологии» ФМБА России: 105077, Москва, ул. 11-я Парковая, 32 корп. 4;РоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, Russia;Russian FederationФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Минздрава России: 117513, Москва, ул. Островитянова, 1, стр. 9;РоссияN.I.Pirogov Russian State National Research Medical University, Healthcare Ministry of Russia: 1, Ostrovityanova str., Moscow, 117997, Russia;Russian FederationГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России: 119992, Москва, ул. Трубецкая, 8, стр. 2;РоссияI.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia: 8, build. 2, Trubetskaya str., Moscow, 119991, Russia;Russian FederationНаучно-клинический центр интерстициальных и орфанных заболеваний легких им. акад. И.П.Павлова: 197022, Санкт-Петербург, ул. Рентгена, 12;РоссияAcademic and Clinical Center of Interstitial and Orphan Diseases, Academician I.P.Pavlov First Saint-Petersburg State Medical University: 6 – 8, L'va Tolstogo str., Saint-Petersburg, 197089, Russia;Russian FederationГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России: 197022, Санкт-Петербург, ул. Льва Толстого, 6–8;РоссияAcademician I.P.Pavlov First Saint-Petersburg State Medical University, Healthcare Ministry of Russia: 6 – 8, L'va Tolstogo str., Saint-Petersburg, 197089, Russia;Russian FederationФГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России: 125993, Москва, ул. Баррикадная, 2 / 1, стр. 1РоссияRussian State Medical Academy of Postgraduate Physician Training, Healthcare Ministry of Russia: 2/1, Barrikadnaya str., Moscow, 123995, Russia;Russian FederationГБОУ ДПО «Иркутская государственная медицинская академия последипломного образования» Минздрава России: 664049, Иркутск, мкр Юбилейный, 100;РоссияIrkutsk State Medical Academy of Postgraduate Training, Healthcare Ministry of Russia: 100, Yubileynyy microraion, Irkutsk, 664049, Russia;Russian FederationФГБНУ «Центральный НИИ туберкулеза» РАН: 107564, Москва, Яузская аллея, 2РоссияFederal Central Research Institute of Tuberculosis, Russian Medical Science Academy: 2, Yauzskaya walk, Moscow, 107564, RussiaRussian Federation201618102016264399419Copyright © Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Демура С.А., Илькович М.М., Коган Е.А., Самсонова М.В., Сперанская А.А., Тюрин И.Е., Черняев А.Л., Черняк Б.А., Черняк А.В., Шмелев Е.И., 20162016Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Демура С.А., Илькович М.М., Коган Е.А., Самсонова М.В., Сперанская А.А., Тюрин И.Е., Черняев А.Л., Черняк Б.А., Черняк А.В., Шмелев Е.И.Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevskiy A.S., Demura S.A., Il'kovich M.M., Kogan E.A., Samsonova M.V., Speranskaya A.A., Tyurin I.E., Chernyaev A.L., Chernyak B.A., Chernyak A.V., Shmelev E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/741

Представлены современные подходы к диагностике и терапии идиопатического легочного фиброза (ИЛФ). Клинические рекомендации направлены на улучшение ранней диагностики, повышение эффективности немедикаментозной и лекарственной терапии ИЛФ, а также качества медицинской помощи при данном заболевании. Данные Рекомендации адресованы пульмонологам, терапевтам и другим специалистам, организаторам и экспертным организациям практического здравоохранения.

This article contains clinical guidelines and current approaches to diagnosis and treatment of idiopathic pulmonary fibrosis (IPF). The aims of development this guidelines were to improve early detection and efficacy of pharmacological and non-pharmacological therapy of IPF. Achieving these goals indicates improvement in medical care quality for these patients. These guidelines are intended to pulmonologists, therapeutists and other medical specialists, healthcare managers and other healthcare providers

обычная интерстициальная пневмониянеспецифическая интерстициальная пневмонияидиопатический легочный фиброзusual interstitial pneumonianon-specific interstitial pneumoniaidiopathic pulmonary fibrosisReferencesRaghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis; evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.Raghu G., Rochwerg B., Zhang Y. et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: executive summary an update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3–e19.Raghu G., Rochwerg B., Zhang Y. et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: executive summary an update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3–e19.Travis W.D., Costabe U., Hansell D.M.et al. An official American Thoracic Society / European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–748.Travis W.D., Costabe U., Hansell D.M.et al. An official American Thoracic Society / European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–748.Ryu J.H., Moua T., Daniels C.E. et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo. Clin. Proc. 2014; 89: 1130–1142.Ryu J.H., Moua T., Daniels C.E. et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo. Clin. Proc. 2014; 89: 1130–1142.Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease. Proc. Am. Thorac. Soc. 2006; 3: 293–298.Taskar V.S., Coultas D.B. Is idiopathic pulmonary fibrosis an environmental disease. Proc. Am. Thorac. Soc. 2006; 3: 293–298.El-Serag H.B., Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997; 113: 755–760.El-Serag H.B., Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997; 113: 755–760.Lee J.S., Song J.W., Wolters P.J. et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39: 352–358.Lee J.S., Song J.W., Wolters P.J. et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur. Respir. J. 2012; 39: 352–358.Garcıa-Sancho Figueroa M.C., Carrillo G., Perez-Padilla R. et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir. Med. 2010; 104: 305–309.Garcıa-Sancho Figueroa M.C., Carrillo G., Perez-Padilla R. et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir. Med. 2010; 104: 305–309.Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Ann. Rev. Pathol. 2014; 9: 157–179.Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Ann. Rev. Pathol. 2014; 9: 157–179.Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006; 79: 149–154.Hodgson U., Pulkkinen V., Dixon M. et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 2006; 79: 149–154.Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 810–816.Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 810–816.Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967–972.Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994; 150: 967–972.Nalysnyk L., Cid-Ruzafa J., Rotella P. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21: 355–361.Nalysnyk L., Cid-Ruzafa J., Rotella P. et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev. 2012; 21: 355–361.Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237.Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237.Johnston I.D.A., Prescott R.J., Chalmers J.C. et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax. 1997; 52: 38–44.Johnston I.D.A., Prescott R.J., Chalmers J.C. et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax. 1997; 52: 38–44.du Bois R.M., Wells A.U. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur. Respir. J. 2001; 18 (Suppl. 32): 43s–55s.du Bois R.M., Wells A.U. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur. Respir. J. 2001; 18 (Suppl. 32): 43s–55s.Piirila P., Sovijarvi A.R.A. Crackles: recording, analysis and clinical significance. Eur. Respir. J. 1995; 8: 2139–2148.Piirila P., Sovijarvi A.R.A. Crackles: recording, analysis and clinical significance. Eur. Respir. J. 1995; 8: 2139–2148.Flaherty K.R., King T.E. Jr, Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a ultidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904–910.Flaherty K.R., King T.E. Jr, Raghu G. et al. Idiopathic interstitial pneumonia: what is the effect of a ultidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904–910.Monaghan H., Wells A.U., Colby T.V. et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004; 125: 522–526.Monaghan H., Wells A.U., Colby T.V. et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004; 125: 522–526.Flaherty K.R., Travis W.D., Colby T.V. et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2001; 164: 1722–1727.Flaherty K.R., Travis W.D., Colby T.V. et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2001; 164: 1722–1727.Miller J.D., Urschel J.D., Cox G. et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann. Thorac. Surg. 2000; 70: 1647–1650.Miller J.D., Urschel J.D., Cox G. et al. A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann. Thorac. Surg. 2000; 70: 1647–1650.Carnochan F.M., Walker W.S., Cameron E.W. Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax. 1994; 49: 361–363.Carnochan F.M., Walker W.S., Cameron E.W. Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax. 1994; 49: 361–363.Leslie K.O., Gruden J.F., Parish J.M., Scholand M.B. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease. Arch. Pathol. Lab. Med. 2007; 131: 407–423.Leslie K.O., Gruden J.F., Parish J.M., Scholand M.B. Transbronchial biopsy interpretation in the patient with diffuse parenchymal lung disease. Arch. Pathol. Lab. Med. 2007; 131: 407–423.Grenier P., Valeyre D., Cluzel P. et al. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology. 1991; 179: 123–132.Grenier P., Valeyre D., Cluzel P. et al. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology. 1991; 179: 123–132.Hansell D.M., Bankier A.A., MacMahon H. et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246: 697–722.Hansell D.M., Bankier A.A., MacMahon H. et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246: 697–722.Johkoh T., Sakai F., Noma S. et al. Honeycombing on CT: its definitions, pathologic correlation, and future directionof its diagnosis. Eur. J. Radiol. 2014; 83: 27–31.Johkoh T., Sakai F., Noma S. et al. Honeycombing on CT: its definitions, pathologic correlation, and future directionof its diagnosis. Eur. J. Radiol. 2014; 83: 27–31.Sverzellati N., Wells A.U., Tomassetti S. et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology. 2010; 254: 957–964.Sverzellati N., Wells A.U., Tomassetti S. et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology. 2010; 254: 957–964.Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46: 186–196.Behr J., Kreuter M., Hoeper M.M. et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46: 186–196.Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 1990. 84: 365–369.Wiggins J., Strickland B., Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir. Med. 1990. 84: 365–369.Doherty M.J., Pearson M.G., O’Grady E.A. et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax. 1997. 52: 998–1002.Doherty M.J., Pearson M.G., O’Grady E.A. et al. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax. 1997. 52: 998–1002.Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 2011; 184: 1382–1389.du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 2011; 184: 1382–1389.Nathan S.D., du Bois R.M., Albera C. et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir. Med. 2015; 109: 914–922.Nathan S.D., du Bois R.M., Albera C. et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir. Med. 2015; 109: 914–922.Nicholson A.G. Interstitial pneumonias. In: Cagle P.T., Fraire A.E., Tomashefski J.F. Jr., Farver C.F., eds. Dail and Hammar's Pulmonary Pathology. Springer Science + Business Media, LLC; 2008: 695–721.Nicholson A.G. Interstitial pneumonias. In: Cagle P.T., Fraire A.E., Tomashefski J.F. Jr., Farver C.F., eds. Dail and Hammar's Pulmonary Pathology. Springer Science + Business Media, LLC; 2008: 695–721.Agarwal R., Jindal S.K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur. J. Intern. Med. 2008; 19: 227–235.Agarwal R., Jindal S.K. Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur. J. Intern. Med. 2008; 19: 227–235.Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001; 345: 517–525.Gross T.J., Hunninghake G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2001; 345: 517–525.King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171–1181.King T.E., Tooze J.A., Schwarz M.I. et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am. J. Respir. Crit. Care Med. 2001; 164: 1171–1181.Kim D.S., Collard H.R., King T.E. Classification and natural history of the idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 285–292.Kim D.S., Collard H.R., King T.E. Classification and natural history of the idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. 2006; 3: 285–292.Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbations of idiopathic pulmonary fibrosis. An International Working Group Report. Am. J. Respir. Crit. Care Med. 2016; 194: 265–275.Collard H.R., Ryerson C.J., Corte T.J. et al. Acute exacerbations of idiopathic pulmonary fibrosis. An International Working Group Report. Am. J. Respir. Crit. Care Med. 2016; 194: 265–275.Akira M., Hamada H., Sakatani M. et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am. J. Roentgenol. 1997; 168: 79–83.Akira M., Hamada H., Sakatani M. et al. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am. J. Roentgenol. 1997; 168: 79–83.Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22: 821–826.Ambrosini V., Cancellieri A., Chilosi M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur. Respir. J. 2003; 22: 821–826.Konishi K., Gibson K.F., Lindell K.O. et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 180: 167–175.Konishi K., Gibson K.F., Lindell K.O. et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 180: 167–175.Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27: 143–150.Kim D.S., Park J.H., Park B.K. et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur. Respir. J. 2006; 27: 143–150.Kondoh Y., Taniguchi H., Kitaichi M. et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir. Med. 2006; 100: 1753–1759.Kondoh Y., Taniguchi H., Kitaichi M. et al. Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir. Med. 2006; 100: 1753–1759.Hiwatari N., Shimura S., Takishima T., Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J. Exp. Med. 1994; 174: 379–386.Hiwatari N., Shimura S., Takishima T., Shirato K. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J. Exp. Med. 1994; 174: 379–386.Parambil J.G., Myers J.L., Ryu J.H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005; 128: 3310–3315.Parambil J.G., Myers J.L., Ryu J.H. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005; 128: 3310–3315.Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26: 586–593.Cottin V., Nunes H., Brillet P.Y. et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26: 586–593.Stahel R.A., Gilks W.R., Lehmann H.P., Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int. J. Cancer. Suppl. 1994; 8: 6–26.Stahel R.A., Gilks W.R., Lehmann H.P., Schenker T. Third International Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int. J. Cancer. Suppl. 1994; 8: 6–26.Kohno N., Kyoizumi S., Awaya Y. et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest. 1989; 96: 68–73.Kohno N., Kyoizumi S., Awaya Y. et al. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest. 1989; 96: 68–73.Авдеева О.Е., Лебедин Ю.С., Авдеев С.Н. и др. Гликозилированный муцин-антиген 3EG5 − сывороточный маркер активности и тяжести при интерстициальных заболеваниях легких. Пульмонология. 1998; 2: 22–27.Avdeeva O.E., Lebedin Yu.S., Avdeev S.N. et al. Glycosylated mucin antigen 3EG5 is a serum marker of activity and severity of interstitial lung disease. Pul'monologiya. 1998; 2: 22–27 (in Russian).Greene K.E., King T.E. Jr, Kuroki Y. et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 439–446.Greene K.E., King T.E. Jr, Kuroki Y. et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 439–446.Shinoda H., Tasaka S., Fujishima S. et al. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration. 2009; 78: 285–292.Shinoda H., Tasaka S., Fujishima S. et al. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration. 2009; 78: 285–292.Leuchte H.H., Baumgartner R.A., Nounou M.E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744–750.Leuchte H.H., Baumgartner R.A., Nounou M.E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744–750.Rosas I.O., Richards T.J., Konishi K. et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5: e93.Rosas I.O., Richards T.J., Konishi K. et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5: e93.Phelps D.S., Umstead T.M., Mejia M. et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest. 2004; 125: 617–625.Phelps D.S., Umstead T.M., Mejia M. et al. Increased surfactant protein-A levels in patients with newly diagnosed idiopathic pulmonary fibrosis. Chest. 2004; 125: 617–625.McCormack F.X., King T.E. Jr, Bucher B.L. et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995; 152: 751–759.McCormack F.X., King T.E. Jr, Bucher B.L. et al. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1995; 152: 751–759.Moeller A., Gilpin S.E., Ask K. et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588–594.Moeller A., Gilpin S.E., Ask K. et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009; 179: 588–594.Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD003134.Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD003134.Richeldi L., Davies H.R., Ferrara G., Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD002880.Richeldi L., Davies H.R., Ferrara G., Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD002880.Gay S.E., Kazerooni E.A., Toews G.B. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063–1072.Gay S.E., Kazerooni E.A., Toews G.B. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063–1072.Flaherty K.R., Toews G.B., Lynch J.P. III et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001; 110: 278–282.Flaherty K.R., Toews G.B., Lynch J.P. III et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med. 2001; 110: 278–282.Demedts M., Behr J., Buhl R. et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242.Demedts M., Behr J., Buhl R. et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353 (21): 2229–2242.Oldham J.M., Ma S.-F., Martinez F.J. et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2015; 192: 1475–1482.Oldham J.M., Ma S.-F., Martinez F.J. et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2015; 192: 1475–1482.Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968–1977.Raghu G., Anstrom K.J., King T.E. Jr et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968–1977.Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079–1087.Richeldi L., Costabel U., Selman M. et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079–1087.Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–2082.Oku H., Shimizu T., Kawabata T. et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008; 590: 400–408.Oku H., Shimizu T., Kawabata T. et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008; 590: 400–408.King T.E. Jr, Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–2092.King T.E. Jr, Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–2092.Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161: 1172–1178.Douglas W.W., Ryu J.H., Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 2000; 161: 1172–1178.Morrison D.A., Stovall J.R. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest. 1992; 102: 542–550.Morrison D.A., Stovall J.R. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest. 1992; 102: 542–550.Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet. 1981; 1: 681–686.Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet. 1981; 1: 681–686.Mason D.P., Brizzio M.E., Alster J.M. et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann. Thorac. Surg. 2007; 84: 1121–1128.Mason D.P., Brizzio M.E., Alster J.M. et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann. Thorac. Surg. 2007; 84: 1121–1128.Keating D., Levvey B., Kotsimbos T. et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant. Proc. 2009; 41: 289–291.Keating D., Levvey B., Kotsimbos T. et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant. Proc. 2009; 41: 289–291.Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126: 469–475.Thabut G., Mal H., Castier Y. et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J. Thorac. Cardiovasc. Surg. 2003; 126: 469–475.Egan J.J., Martinez F.J., Wells A.U., Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005; 60: 270–273.Egan J.J., Martinez F.J., Wells A.U., Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005; 60: 270–273.Thabut G., Christie J.D., Ravaud P. et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2009; 151: 767–774.Thabut G., Christie J.D., Ravaud P. et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2009; 151: 767–774.Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120: 213–219.Stern J.B., Mal H., Groussard O. et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest. 2001; 120: 213–219.Al-Hameed F.M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can. Respir. J. 2004; 11: 117–122.Al-Hameed F.M., Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can. Respir. J. 2004; 11: 117–122.Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010; 79: 209–215.Mollica C., Paone G., Conti V. et al. Mechanical ventilation in patients with end-stage idiopathic pulmonary fibrosis. Respiration. 2010; 79: 209–215.Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir. Med. 2008; 102: 1355–1359.Mallick S. Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit. Respir. Med. 2008; 102: 1355–1359.Holland A.E., Hill C.J., Conron M. et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008; 63: 549–554.Holland A.E., Hill C.J., Conron M. et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008; 63: 549–554.Nishiyama O., Kondoh Y., Kimura T. et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008; 13: 394–399.Nishiyama O., Kondoh Y., Kimura T. et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008; 13: 394–399.Ferreira A., Garvey C., Connors G.L. et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009; 135: 442–447.Ferreira A., Garvey C., Connors G.L. et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009; 135: 442–447.Jastrzebski D., Gumola A., Gawlik R., Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J. Physiol. Pharmacol. 2006; 57: 139–148.Jastrzebski D., Gumola A., Gawlik R., Kozielski J. Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J. Physiol. Pharmacol. 2006; 57: 139–148.Naji N.A., Connor M.C., Donnelly S.C., McDonnell T.J. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J. Cardiopulm. Rehabil. 2006; 26: 237–243.Naji N.A., Connor M.C., Donnelly S.C., McDonnell T.J. Effectiveness of pulmonary rehabilitation in restrictive lung disease. J. Cardiopulm. Rehabil. 2006; 26: 237–243.Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360: 895–900.Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360: 895–900.Madden B.P., Allenby M., Loke T., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol. 2006; 44: 372–376.Madden B.P., Allenby M., Loke T., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul. Pharmacol. 2006; 44: 372–376.Collard H.R., Anstrom K.J., Schwarz M.I., Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131: 897–899.Collard H.R., Anstrom K.J., Schwarz M.I., Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131: 897–899.Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir. Med. 2008; 102: 1015–1020.Minai O.A., Sahoo D., Chapman J.T., Mehta A.C. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir. Med. 2008; 102: 1015–1020.Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006; 129: 794–800.Raghu G., Yang S.T., Spada C. et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006; 129: 794–800.Linden P.A., Gilbert R.J., Yeap B.Y. et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131: 438–446.Linden P.A., Gilbert R.J., Yeap B.Y. et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J. Thorac. Cardiovasc. Surg. 2006; 131: 438–446.Lee J.S., Ryu J.H., Elicker B.M. et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 1390–1394.Lee J.S., Ryu J.H., Elicker B.M. et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 1390–1394.Savarino E., Bazzica M., Zentilin P. et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med. 2009; 179: 408–413.Savarino E., Bazzica M., Zentilin P. et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med. 2009; 179: 408–413.Gulmez S.E., Holm A., Frederiksen H. et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 2007; 167: 950–955.Gulmez S.E., Holm A., Frederiksen H. et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 2007; 167: 950–955.Yang Y.X., Lewis J.D., Epstein S. et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296: 2947–2953.Yang Y.X., Lewis J.D., Epstein S. et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296: 2947–2953.Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.Collard H.R., King T.E. Jr, Bartelson B.B. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 538–542.King T.E. Jr, Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005; 127: 171–177.King T.E. Jr, Safrin S., Starko K.M. et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005; 127: 171–177.Zappala C.J., Latsi P.I., Nicholson A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 830–836.Zappala C.J., Latsi P.I., Nicholson A.G. et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 830–836.Raghu G., Brown K.K., Bradford W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125–133.Raghu G., Brown K.K., Bradford W.Z. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2004; 350: 125–133.Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040–1047.Azuma A., Nukiwa T., Tsuboi E. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040–1047.ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111–117.ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111–117.

The authors declare that there are no conflicts of interest present.